Conditions: Head and Neck Neoplasms Carcinoma, Squamous Cell
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 124
Healthy volunteers: no

Brief summary:
The primary objective of this study is to explore the efficacy of BIBW 2992 compared with cetuximab (Erbitux) in patients with metastatic or recurrent head and neck cancer after failure of platinum-containing therapy. In addition, the trial aims to clarify the influence of EGFR genotype on tumor response to the treatment regimens.

Detailed description:

Arms:
arm 1: once daily taken orally arm 2: once every week by intravenous injection

Interventions: intervention 1: BIBW 2992 intervention 2: Cetuximab
Intervention descriptions: intervention 1: experimental drug taken once daily orally intervention 2: active comparator administered weekly intravenously

Protocol document: